Enveda Biosciences Closes $68-Million Combined Series B Equity And Debt Financing

Dec 21, 2022•almost 3 years ago

Round Type

series b

Boulder

Investors

Two Sigma VenturesHummingbird VenturesWireframe VenturesLux CapitalTrue VenturesPossible VenturesLevel VenturesJazz Venture Partners

Description

Enveda Biosciences today announced that it has closed a $68-million equity and debt financing. Dimension led the Series B round, which included participation by multiple new institutional investors, including FPV, Jazz Venture Partners, Level Ventures, Amino Collective, Allen & Co, and Possible Ventures. All of Enveda’s current major investors, including True Ventures, Lux Capital, Wireframe Ventures, Hummingbird Ventures, and Two Sigma Ventures, also participated in the round.

Company Information

Company

Enveda Biosciences

Location

1880 S Flatiron Ct. Ste. K

Boulder, Colorado, United States

About

Enveda Biosciences is a biotechnology company building the first high-resolution chemical map of the natural world to tackle the toughest problems in drug discovery. Enveda’s platform is the world’s most advanced drug discovery search engine for dark chemical space, building on years of cutting-edge advancements at the intersection of metabolomics and machine learning. Complementing its breakthrough technology, Enveda’s team includes seasoned drug hunters with decades of experience in the pharmaceutical industry working alongside world-leading data scientists. For more information on Enveda, visit envedabio.com.

Related People

7 contacts

Funding Insights

Based on industry data

VC-backed spending patterns